AngioDynamics Appoints Eric Honroth as President and Chief Executive Officer

October 9, 2026—AngioDynamics, Inc. announced the appointment of Eric Honroth as President, Chief Executive Officer, and a member of the company’s board of directors.

Effective November 2, 2026, Honroth will succeed Jim Clemmer, who will depart the board and remain in a consulting capacity.

According to AngioDynamics, Honroth brings more than 20 years of medical device and life sciences leadership experience across markets directly aligned with the company’s portfolio, including cardiovascular, endovascular, urology and oncology. His career provides a proven foundation for advancing the company’s strategic growth and value-creation priorities, stated the company.

Most recently, Honroth served as Global President, Life Science at Getinge. Previously, he led Getinge’s $1.2 billion North American business, where he accelerated growth, delivered sustained revenue gains, and strengthened operational performance through new product development and strategic portfolio management.

Additionally, he has held senior leadership roles at Abbott Vascular, Becton Dickinson, CareFusion, and Boston Scientific. His leadership experience spans both North American and global markets, including responsibility for large-scale commercial organizations and global business operations.

Howard Donnelly, AngioDynamics Board Chair, commented on the appointment of Honroth in the company’s press release.

“AngioDynamics enters this transition with real momentum, including a high-growth med tech segment, a strong balance sheet with no outstanding debt, and an operational transformation that is delivering,” stated Donnelly. “Eric has done what this moment requires. He has built businesses, driven profitable growth, and managed global operations with responsibility for both revenue and cost structure. He also builds teams and leads with a genuine commitment to patients, and the board is confident he is the right leader to deliver long-term value during our next chapter.”

Donnelly continued, “On behalf of the board, I want to thank Jim for his exceptional leadership over the past decade. Under his guidance, AngioDynamics underwent a successful transformation that sharpened our focus and built a solid foundation for sustainable growth and profitability. Jim’s dedication to our team, patients, customers, and shareholders has left a lasting mark on the company, and we are deeply grateful for his many contributions. We look forward to his continued contributions as a trusted senior advisor.”